Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks

Hypertension Research

Volumn 39, Issue 5, 2016, Pages 277-292

  Hermida, Ramón C ^a   Ayala, Diana E ^a   Smolensky, Michael H ^b   Fernández, José R ^a   Mojón, Artemio ^a   Portaluppi, Francesco ^c  

^a UNIVERSITY OF VIGO   (Spain)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

ambulatory blood pressure monitoring; asleep blood pressure; cardiovascular risk; diabetes; hypertension chronotherapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BIOENGINEERING; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DEATH; DIABETES MELLITUS; DISEASE CONTROL; DRUG CHRONOTHERAPY; HEART INFARCTION; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; NONDIPPER HYPERTENSION; PROGNOSTIC ASSESSMENT; RESISTANT HYPERTENSION; REVIEW; RISK REDUCTION; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASES; CHRONOPHARMACOLOGY; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; STROKE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG CHRONOTHERAPY; HUMANS; HYPERTENSION; RISK REDUCTION BEHAVIOR; STROKE; TREATMENT OUTCOME;

EID: 84966713027     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.142     Document Type: Review

References (145)

1. Duguay D, Cermakian N. The crosstalk between physiology and circadian clock proteins. Chronobiol Int 2009; 26: 1479-1513.
2. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002; 418: 935e41.
3. Albrecht U. Timing to perfection: the biology of central and peripheral clocks. Neuron 2012; 74: 246e60.
4. Hermida RC, Fernández JR, Ayala DE, Mojón A, Alonso I, Smolensky M. Circadian rhythm of double (rate-pressure) product in healthy normotensive young subjects. Chronobiol Int 2001; 18: 475-489.
5. Hermida RC, Ayala DE, Fernández JR, Mojón A, Alonso I, Calvo C. Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol Int 2002; 19: 461-481.
6. Hermida RC, Calvo C, Ayala DE, Mojón A, López JE. Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J Hypertens 2002; 20: 1097-1104.
7. Portaluppi F, Vergnani L, Manfredini R, Fersini C. Endocrine mechanisms of blood pressure rhythms. Ann NY Acad Sci 1996; 783: 113-131.
8. Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv Drug Deliv Rev 2007; 59: 904-922.
9. Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian rhythms and cardiovascular health. Sleep Med Rev 2012; 16: 151-166.
10. Fabbian F, Smolensky MH, Tiseo R, Pala M, Manfredini R, Portaluppi F. Dipper and non-dipper blood pressure 24-hour patterns: circadian rhythm-dependent physiologic and pathophysiologic mechanisms. Chronobiol Int 2013; 30: 17-30.
11. Lakatua DJ, Haus E, Halberg F, Halberg E, Wendt HW, Sackett-Lundeen LL, Berg HG, Kawasaki T, Ueno M, Uezono K, Matsuoka M, Omae T. Circadian characteristics of urinary epinephrine and norepinephrine from healthy young women in Japan and U.S.A. Chronobiol Int 1986; 3: 189-195.
12. Angeli A, Gatti G, Masera R. Chronobiology of the hypothalamic-pituitary-adrenal and renin-angiotensin-aldosterone systems. In: Touitou Y, Haus E (eds). Biologic Rhythms in Clinical and Laboratory Medicine. Springer-Verlag: Berlin, 1992, pp 292-314.
13. Kool MJ, Wijnen JA, Derkx FH, Struijker Boudier HA, Van Bortel LM. Diurnal variation in prorenin in relation to other humoral factors and hemodynamics. Am J Hypertens 1994; 7: 723-730.
14. Bartter FC, Chan JCM, Simpson HW. Chronobiological aspect of plasma renin activity, plasma aldosterone and urinary electrolytes. In: Krieger DT (ed). Endocrine Rhythms. Raven: New York. 1979 pp 49-132.
15. Portaluppi F, Trasforini G, Margutti A, Vergnani L, Ambrosio MR, Rossi R, Bagni B, Pansini R, degli Uberti EC. Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J Hypertens 1992; 10: 1227-1234.
16. Sothern RB, Vesely DL, Kanabrocki EL, Hermida RC, Bremner FW, JLHC Third, Boles MA, Nemchausky BM, Olwin JH, Scheving LE. Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure. Chronobiol Int 1995; 12: 106-120.
17. Smolensky MH, Hermida RC, Castriotta RJ, Portaluppi F. Role of sleep-wake cycle on blood pressure circadian rhythms and hypertension. Sleep Med 2007; 8: 668-680.
18. Hermida RC, Smolensky MH, Ayala DE, Portaluppi F, Crespo JJ, Fabbian F, Haus E, Manfredini R, Mojón A, Moyá A, Piñeiro L, Ríos MT, Otero A, Balan H, Fernández JR. 2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM). Chronobiol Int 2013; 30: 355-410.
19. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
20. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
21. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415.
22. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156-161.
23. Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Ishikawa S, Schwartz J, Shimada K, Kario K. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am J Hypertens 2008; 21: 443-450.
24. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168: 2340-2346.
25. Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, Cianciaruso B, Zamboni P, Conte G, Gabbai FB, De Nicola L. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 2011; 171: 1090-1098.
26. The ABC-H Investigators, Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P, Eguchi K, Kario K, Hoshide S, Polonia J, de la Sierra A, Hermida RC, Dolan E, Zamalloa H. Prognostic impact from clinic, daytime, and nighttime systolic blood pressure in 9 cohorts on 13,844 patients with hypertension. J Hypertens 2014; 32: 2332-2340.
27. Portaluppi F, Hermida RC. Circadian rhythms in cardiac arrhythmias and opportunities for their chronotherapy. Adv Drug Deliv Rev 2007; 59: 940-951.
28. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852-857.
29. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002; 20: 2183-2189.
30. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen CH, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007; 370: 1219-1229.
31. Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 2011; 58: 1165-1173.
32. Hermida RC, Ayala DE, Fernández JR, Mojón A. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol Int 2013; 30: 68-86.
33. Hermida RC, Ayala DE, Mojón A, Fernández JR. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level - the "normotensive non-dipper" paradox. Chronobiol Int 2013; 30: 87-98.
34. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 2005; 45: 240-245.
35. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension 2007; 49: 1235-1241.
36. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: 55-61.
37. Hermida RC, Ayala DE, Mojón A, Fernández JR. Sleep-time blood pressure and the prognostic value of isolated-office and masked hypertension. Am J Hypertens. 2012; 25: 297-305.
38. Hermida RC, Ayala DE, Mojón A, Fernández JR. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens 2012; 25: 325-334.
39. Ayala DE, Hermida RC, Mojón A, Fernández JR. Cardiovascular risk of resistant hypertension: Dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int 2013; 30: 340-352.
40. Hermida RC, Ayala DE, Mojón A, Smolensky MH, Portaluppi F, Fernández JR. Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction. J Hum Hypertens 2014; 28: 567-574.
41. Hermida RC, Smolensky MH, Ayala DE, Portaluppi F. Ambulatory blood pressure monitoring (ABPM) as the reference standard for diagnosis of hypertension and assessment of vascular risk in adults. Chronobiol Int (e-pub ahead of print 20 November 2015).
42. Smolensky MH, Ayala DE, Hermida RC. Ambulatory blood pressure monitoring (ABPM) as THE reference standard to confirm diagnosis of hypertension in adults: recommendation of the 2015 U.S. Preventive Services Task Force (USPSTF). Chronobiol Int 2015; 32: 1320-1322.
43. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol Int 2010; 27: 1629-1651.
44. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011; 34: 1270-1276.
45. Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313-2321.
46. Hermida RC, Ayala DE, Mojón A, Fernández JR. Cardiovascular risk of essential hypertension: Influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol Int 2013; 30: 315-327.
47. Hermida RC, Ayala DE, Mojón A, Fernández JR. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Chronobiol Int 2013; 30: 328-339.
48. Hermida RC, Ayala DE, Mojón A, Fernández JR, Sleep-time BP. Prognostic marker of type 2 diabetes and therapeutic target for prevention. Diabetologia 2015 (in press) doi:10.1007/s00125-015-3748-8 [e-pub ahead of print].
49. Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial. Diabetologia 2015 (in press) doi:10.1007/s00125-015-3749-7 [e-pub ahead of print].
50. Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Ambulatory blood pressure monitoring: Importance of sampling rate and duration - 48 versus 24 hours - on the accurate assessment of cardiovascular risk. Chronobiol Int 2013; 30: 55-67.
51. Hermida RC, Ayala DE, Crespo JJ, Mojón A, Chayán L, Fontao MJ, Fernández JR. Influence of age and hypertension treatment-time on ambulatory blood pressure in hypertensive patients. Chronobiol Int 2013; 30: 176-191.
52. Hermida RC, Fernández JR, Mojón A, Ayala DE. Reproducibility of the hyperbaric index as a measure of blood pressure excess. Hypertension 2000; 35: 118-125.
53. Hermida RC, Mojón A, Fernández JR, Alonso I, Ayala DE. The tolerance-hyperbaric test: a chronobiologic approach for improved diagnosis of hypertension. Chronobiol Int 2002; 19: 1183-1211.
54. Crespo C, Aboy M, Fernández JR, Mojón A. Automatic identification of activity-rest periods based on actigraphy. Med Biol Eng Comput 2012; 50: 329-340.
55. Crespo C, Fernández JR, Aboy M, Mojón A. Clinical application of a novel automatic algorithm for actigraphy-based activity and rest period identification to accurately determine awake and asleep ambulatory blood pressure parameters and cardiovascular risk. Chronobiol Int 2013; 30: 43-54.
56. Bélanger PM, Bruguerolle B, Labrecque G. Rhythms in pharmacokinetics: absorption, distribution, metabolism. In:Redfern PH, Lemmer B (eds). Physiology and Pharmacology of Biological Rhythms. Handbook of Experimental Pharmacology series, Vol 125. Springer-Verlag: Berlin-New York, 1997, pp 177-204.
57. Labrecque G, Beauchamp D. Rhythms and pharmacokinetics. In: Redfern P (ed). Chronotherapeutics. Pharmaceutical Press: London, 2003, pp 75-110.
58. Okyar A, Dressler C, Hanafy A, Baktir G, Lemmer B, Spahn-L12uth H. Circadian variations in exsorptive transport: in-situ intestinal perfusion data and in-vivo relevance. Chronobiol Int 2012; 29: 443-453.
59. Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. Chronotherapy of hypertension: administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv Drug Deliv Rev 2007; 59: 923-939.
60. Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. Administration-time-dependent effect of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit 2010; 15: 173-180.
61. Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens 2011; 24: 383-391.
62. Smolensky MH, Siegel RA, Haus E, Hermida RC, Portaluppi F. Biological rhythms, drug delivery, and chronotherapeuticsInSiepmann J, Siegel RA, Rathbone MJ (eds). Fundamentals and Applications of Controlled Release Drug Delivery. Springer-Verlag: Heildelberg, 2012, pp 359-443.
63. Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F. Administration-time-differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 2013; 30: 280-314.
64. Hermida RC, Ayala DE, Smolensky MH, Mojón A, Fernández JR, Crespo JJ, Moyá A, Ríos MT, Portaluppi F. Chronotherapy improves blood pressure control and reduces vascular risk in CKD. Nat Rev Nephrol 2013; 9: 358-368.
65. Hermida RC, Ríos MT, Crespo JJ, Moyá A, Domínguez-Sardiña M, Otero A, Sánchez JJ, Mojón A, Fernández JR, Ayala DE. on behalf on the Hygia Project Investigators. Treatment-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertension. Chronobiol Int 2013; 30: 192-206.
66. Hermida RC, Ayala DE, Smolensky MH, Fernández JR, Mojón A, Crespo JJ, Ríos MT, Moyá A, Portaluppi F. Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders. Curr Hypertens Rep 2014; 16: 412.
67. Hermida RC, Ayala DE, Smolensky MH, Mojón A, Fernández JR, Portaluppi F. Chronotherapy of hypertension with ACEIs and CKD - a new solution to an old problem. In:Onuigbo M (ed).ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics Vol 2. Nova Science Publishers Inc: Hauppauge, NY, 2014, pp 3-39.
68. Hermida RC, Smolensky MH, Ayala DE, Fernández JR, Moyá A, Crespo JJ, Mojón A, Ríos MT, Fabbian F, Portaluppi F. Abnormalities in chronic kidney disease of ambulatory blood pressure 24h patterning and normalization by bedtime hypertension chronotherapy. Nephrol Dial Transplant 2014; 29: 1160-1167.
69. Smolensky MH, Hermida RC, Ayala DE, Portaluppi F. Bedtime hypertension chronotherapy: concepts and patient outcomes. Curr Pharm Des 2015; 21: 773-790.
70. Witte K, Lemmer B. Rhythms and pharmacodynamics. In:Redfern P (ed).Chronotherapeutics. Pharmaceutical Press: London, 2003, pp 111-126.
71. Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009; 54: 40-46.
72. Hermida RC, Ayala DE, Fontao MJ, Mojón A, Alonso I, Fernández JR. Administration-time- dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int 2010; 27: 560-574.
73. Balan H, Popescu E, Angelescu G. Comparing different treatment schedules of Zomen (zofenopril). Rom J Intern Med 2011; 49: 75-84.
74. Ohmori M, Fujimura A. ACE inhibitors and chronotherapy. Clin Exp Hypertens 2005; 2 & 3: 179-185.
75. Sunaga K, Fujimura A, Shiga T, Ebihara A. Chronopharmacology of enalapril in hypertensive patients. Eur J Clin Pharmacol 1995; 48: 441-445.
76. Fujimura A, Ebihara A, Shiigai T, Shimada K, Tagawa H, Gomi T, Nakamura Y, Suzuki M, Yokozuka H. Amelioration of enalapril-induced dry cough by changing dosing time from morning to evening: a preliminary trial. Jpn J. Clin Pharmacol Ther 1999; 30: 741-744.
77. Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1988; 16: 385-393.
78. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. Administration-time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003; 42: 283-290.
79. Hermida RC, Calvo C, Ayala DE, Fernández JR, Covelo M, Mojón A, López JE. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005; 23: 1913-1922.
80. Hermida RC, Calvo C, Ayala DE, López JE. Decrease in urinary albumin excretion associated to the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005; 46: 960-968.
81. Hermida RC, Calvo C, Ayala DE, Mojón A, Rodríguez M, Chayán L, López JE, Fontao MJ, Soler R, Fernández JR. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int 2005; 22: 755-776.
82. Hermida RC, Ayala DE, Calvo C. Optimal timing of antihypertensive dosing: focus on valsartan. Ther Clin Risk Manag 2007; 3: 119-131.
83. Hermida RC, Ayala DE, Fernández JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007; 50: 715-722.
84. Hermida RC, Ayala DE, Chayán L, Mojón A, Fernández JR. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 2009; 26: 61-79.
85. Kario K, Hoshide S, Shimizu M, Yano Y, Eguchi K, Ishikawa J, Ishikawa S, Shimada K. Effects of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens 2010; 28: 1574-1583.
86. Eguchi K, Shimizu M, Hoshide S, Shimada K, Kario K. A bedtime dose of ARB was better than a morning dose in improving baroreflex sensitivity and urinary albumin excretion-the J-TOP study. Clin Exp Hypertens 2012; 34: 488-492.
87. Hoshino A, Nakamura T, Matsubara H. The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Clin Exp Hypertens 2010; 32: 416-422.
88. Kasiakogias A, Tsioufis C, Thomopoulos C, Andrikou I, Aragiannis D, Dimitriadis K, Tsiachris D, Bilo G, Sideris S, Filis K, Parati G, Stefanadis C. Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. J Hypertens 2015; 33: 393-400.
89. Zappe DH, Crikelair N, Kandra A, Palatini P. Time of administration important? Morning versus evening dosing of valsartan. J Hypertens 2015; 33: 385-392.
90. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22: 837-846.
91. Hermida RC, Calvo C, Ayala DE, Lopez JE, Rodriguez M, Chayan L, Mojon A, Fontao MJ, Fernandez JR. Dose- and administration-time-dependent effects of nifedipine GITS on ambulatory blood pressure in hypertensive subjects. Chronobiol Int 2007; 24: 471-493.
92. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens 2008; 21: 948-954.
93. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Fontao MJ, López JE. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int 2004; 21: 277-296.
94. Koga H, Hayashi J, Yamamoto M, Kitamoto K. Prevention of morning surge of hypertension by the evening administration of carvedilol. Jap Med Ass J 2005; 48: 398-403.
95. Hermida RC, Calvo C, Ayala DE, Rodríguez M, Chayán L, López JE. Administration time-dependent effects of nebivolol on the diurnal/nocturnal blood pressure ratio in hypertensive patients. J Hypertens 2006; 24 (Suppl 4): S89.
96. Hermida RC, Ayala DE, Mojón A, Chayán L, Domínguez MJ, Fontao MJ, Soler R, Alonso I, Fernández JR. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 2008; 25: 950-970.
97. Middeke M, Kluglich M, Holzgreve H. Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing. Chronobiol Int 1991; 8: 506-510.
98. Meng Y, Zhang Z, Liang X, Wu C, Qi G. Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. Acta Cardiol 2010; 65: 309-314.
99. Zeng J, Jia M, Ran H, Zhang Y, Zhang J, Wang X, Wang H, Yang C, Zeng C. Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study. Hypertens Res 2011; 34: 767-772.
100. Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Chronotherapy with valsartan/amlodipine combination in essential hypertension: improved blood pressure control with bedtime dosing. Chronobiol Int 2010; 27: 1287-1303.
101. Hermida RC, Ayala DE, Mojón A, Fontao MJ, Fernández JR. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int 2011; 28: 601-610.
102. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419.
103. Cugini P. The treatability of refractory or resistant hypertension by personalized antihypertensive chronotherapy based on ambulatory monitoring of the arterial pressure. Recenti Prog Med 1996; 87: 51-57.
104. Hermida RC, Ayala DE, Calvo C, López JE, Mojón A, Fontao MJ, Soler R, Fernández JR. Effects of the time of day of antihypertensive treatment on the ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005; 46: 1053-1059.
105. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008; 51: 69-76.
106. Hermida RC, Ayala DE, Mojón A, Fernández JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am J Hypertens 2010; 23: 432-439.
107. Ríos MT, Domínguez-Sardiña M, Ayala DE, Gomara S, Sineiro E, Pousa L, Callejas PA, Fontao MJ, Fernández JR, Hermida RCon behalf of the Hygia Project Investigators. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int 2013; 30: 207-220.
108. Almirall J, Comas L, Martínez-Ocaña JC, Roca S, Arnau A. Effects of chronotherapy on blood pressure control in non-dipper patients with refractory hypertension. Nephrol Dial Transplant 2012; 27: 1855-1859.
109. Niskikawa T, Omura M, Saito J, Matsuzawa Y. The possibility of resistant hypertension during the treatment of hypertensive patients. Hypertens Res 2013; 36: 924-929.
110. Agarwal R, Nissenson AR, Battle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-297.
111. Portaluppi F, Montanari L, Ferlini M, Gilli P. Altered circadian rhythms of blood pressure and heart rate in non-hemodialysis chronic renal failure. Chronobiol Int 1990; 7: 321-327.
112. Agarwal R, Andersen MJ. Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 2005; 46: 514-520.
113. Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 2006; 166: 846-852.
114. Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RAAfrican American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009; 53: 20-27.
115. Crespo JJ, Piñeiro L, Otero A, Castiñeira C, Ríos MT, Regueiro A, Mojón A, Lorenzo S, Ayala DE, Hermida RCon behalf of the Hygia Project Investigators. Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease. Chronobiol Int 2013; 30: 159-175.
116. Mojón A, Ayala DE, Piñeiro L, Otero A, Crespo JJ, Moyá A, Bóveda J, Pérez de Lis J, Fernández JR, Hermida RCon behalf of the Hygia Project Investigators. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int 2013; 30: 145-158.
117. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluaion and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
118. Minutolo R, Gabbai FB, Borrelli S, Scigliano R, Trucillo P, Baldanza D, Laurino S, Mascia S, Conte G, De Nicola L. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007; 50: 908-917.
119. Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller ER 3rd, Rostand S, Toto R, Wang X, Wright JT Jr, Appel LJ. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension 2013; 61: 82-88.
120. Okeahialam B, Ohihoin E, Ajuluchukwu J. Chronotherapy in Nigerian hypertensives. Ther Adv Cardiovasc Dis 2011; 5: 113-118.
121. Wang C, Zhang J, Liu X, Li CC, Ye ZC, Peng H, Chen Z, Lou T. Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. J Clin Hypertens (Greenwich) 2013; 15: 48-54.
122. Cuspidi C, Meani S, Lonati L, Fusi V, Valerio C, Sala C, Magnaghi G, Maisaidi M, Zanchetti A. Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. J Hypertens 2006; 24: 647-653.
123. Pistrosch F, Reissmann E, Wildbrett J, Koehler C, Hanefeld M. Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients. Am J Hypertens 2007; 20: 541-545.
124. Ayala DE, Moyá A, Crespo JJ, Castiñeira C, Domínguez-Sardiña M, Gomara S, Sineiro E, Mojón A, Fontao MJ, Hermida RCon behalf of the Hygia Project Investigators. Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes. Chronobiol Int 2013; 30: 99-115.
125. Moyá A, Crespo JJ, Ayala DE, Ríos MT, Pousa L, Callejas PA, Salgado JL, Mojón A, Fernández JR, Hermida RCon behalf on the Hygia Project Investigators. Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes. Chronobiol Int 2013; 30: 116-131.
126. Tofé S, García B. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwhich) 2009; 11: 426-431.
127. Rossen NB, Knudsen ST, Fleischer J, Hvas AM, Ebbehoj, Poulsen PL, Hansen KW. Targetting nocturnal hyperetnsion in type 2 diabetes mellitus. Hypertension 2014; 64: 1080-1087.
128. Suzuki K, Aizawa Y. Evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes. Clin Exp Hypertens 2011; 33: 56-62.
129. Qiu YG, Zhu JH, Tao QM, Zheng P, Chen JZ, Hu SJ, Zhang FR, Zheng LR, Zhao LL, Yao XY. Captopril administered at night restores the diurnal blood pressure rhythm in adequately controlled, nondipping hypertensives. Cardiovasc Drugs Ther 2005; 19: 189-195.
130. Takeda A, Toda T, Fujii T, Matsui N. Bedtime administration of long-acting antihypertensive drugs restores normal nocturnal blood pressure fall in nondippers with essential hypertension. Clin Exp Nephrol 2009; 13: 467-472.
131. Farah R, Makhoul N, Arraf Z, Khamisy-Farah R. Switching therapy to bedtime for uncontrolled hypertension with a nondipping pattern: a prospective randomized-controlled study. Blood Press Monit 2013; 18: 227-231.
132. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
133. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
134. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823-1829.
135. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJCONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082.
136. White WB, Black HR, Weber MA, Elliott WJ, Brysinski B, Fakourhi TD. Comparison of effects of controlled-onset extended-release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998; 81: 424-431.
137. Roush GC, Fapohunda J, Kostis JB. Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens (Greenwich) 2014; 16: 561-568.
138. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
139. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012; 35 (Suppl 1): S11-S63.
140. The Task Force of diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD), Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013; 34: 3035-3087.
141. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura SJapanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253-390.
142. Chiang CE, Wang TD, Ueng KC, Lin TH, Yeh HI, Chen CY, Wu YJ, Tsai WC, Chao TH, Chen CH, Chu PH, Chao CL, Liu PY, Sung SH, Cheng HM, Wang KL, Li YH, Chiang FT, Chen JH, Chen WJ, Yeh SJ, Lin SJ2015guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. J Chin Med Assoc 2015; 78: 1-47.
143. Gradman AH. Sleep-time blood pressure. A validated therapeutic target. J Am Coll Cardiol 2011; 58: 1174-1175.
144. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27: 1509-1520.
145. Portaluppi F, Smolensky MH. Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. Chronobiol Int 2010; 27: 1652-1667.